Restoring Lives
One Story At A Time

We are Assertio — an assertive, energetic, and empathetic pharmaceutical company built around the mission of advancing patient care. Formerly known as Depomed, we have transformed our company with a current focus on three FDA-approved products in our core areas of neurology, orphan, and specialty medicines, as we continue to identify, license, and develop new products that offer enhanced options for patients who may be underserved by existing therapies. More

In the News

February 19, 2020

Assertio Therapeutics Announces Repurchase of Approximately $188.0 Million of its Outstanding Convertible DebtRead More

February 13, 2020

Assertio Therapeutics Announces Closing of Sale of NUCYNTA® Franchise to Collegium Pharmaceutical for $375.0 MillionRead More

February 6, 2020

Assertio Therapeutics Announces Sale of NUCYNTA® Franchise to Collegium Pharmaceutical for $375.0 MillionRead More

More News